科美诊断11月21日获融资买入594.64万元，融资余额1.65亿元

Group 1 - The core viewpoint of the news is that Kemei Diagnostics experienced a decline in stock price and trading volume, indicating potential market concerns about its financial performance and investor sentiment [1] - On November 21, Kemei Diagnostics' stock fell by 5.22%, with a trading volume of 53.33 million yuan. The net financing purchase on that day was 471,600 yuan, with a total financing and securities balance of 165 million yuan [1] - The financing balance of Kemei Diagnostics is 165 million yuan, accounting for 5.38% of its circulating market value, which is below the 30th percentile level over the past year, indicating a low financing level [1] Group 2 - As of September 30, Kemei Diagnostics had 10,400 shareholders, a decrease of 0.60% from the previous period, while the average circulating shares per person increased by 0.61% to 38,586 shares [2] - For the period from January to September 2025, Kemei Diagnostics reported operating revenue of 261 million yuan, a year-on-year decrease of 24.13%, and a net profit attributable to shareholders of 41.56 million yuan, down 62.94% year-on-year [2] - Kemei Diagnostics has distributed a total of 306 million yuan in dividends since its A-share listing, with 238 million yuan distributed over the past three years [3]